Search Results
45 results found-
When integrated with workflows within the laboratory environment to increase laboratory facilities, this advanced technology uses an accuracy, enhance result reproducibility and improve augmented reality headset and a linked tablet, to offer efficiency by decoupling productivity from scientists.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
ST. GALLEN, SWITZERLAND, March 28, 2024 / PRNewswire / -- CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
https://newsroom.csl.com/2024-03-28-Vafseo-R-approved-by-the-U-S-FDA-for-the-treatment-of-anemia-due-to-chronic-kidney-disease-in-dialysis-dependent-adult-patients -
3.0 800 8000 1500 700 7000 2.5 1200 600 6000 2.0 5000 500 900 1.5 400 4000 300 3000 600 1.0 200 2000 300 0.5 100 1000 0.0 0 0 0
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
In order to accelerate the commercialisation of promising In June 2020, a strategic alliance was announced with the biomedical research, CSL has committed A$45 million over 10 Seattle Children's Research Institute (SCRI) - one of the top years to the Brandon Capital-led A$230 million Biomedical paediatric research institutions in the world - to develop Translation Fund (BTF) and the two A$200 million Medical stem cell gene therapies for primary immunodeficiency (PI) Research Commercialisation Funds (MRCF3 and MRCF5).
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
Seqirus operates state-of-the-art prevent haemolytic disease in newborns, production facilities in the US, the for urgent warfarin reversal in patients CSL Plasma, a division of CSL Behring, United Kingdom (UK) and Australia and with acute major bleeding, to prevent operates one of the world's largest utilises both egg-based and cell-based infection in solid organ transplant and most efficient plasma collection manufacturing technologies as well as a recipients and treat specific infections, networks, with more than 200 centres proprietary adjuvant.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2018-full.pdf -
68 CSL Limited Annual Report 2017 200 60% 35% 35% 35% 160 43% 43% 43% 43% 43% 60% 120 43% 43% 43% 43% 43% 80 35% 35% 35% 40 120% 70% 85% 70% 85% 85% 70% 85% 85% 0 L Reed L Reed G Boss G Boss G Naylor G Naylor R Repella R Repella D Lamont D Lamont P Perreault P Perreault V Romberg V Romberg K Etchberger K Etchberger A Cuthbertson A Cuthbertson
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2017-full.pdf -
Participated in and received organisation specific (in confidence) insights based on the Australian Council of Superannuation Investors (ACSIs) 2023 review of modern slavery reporting for ASX200 companies.
https://www.csl.com/-/media/csl/documents/csl-statement-on-modern-slavery-2023.pdf -
It is critical to not only uphold all five dimensions of reconciliation, but also CSL Ltd joins a network of more than 2,200 increase awareness of Aboriginal and corporate, government and not-for-profit Torres Strait Islander cultures, histories, organisations that have made a formal knowledge and leadership across all sectors commitment to reconciliation through the of Australian society.
https://www.csl.com/-/media/shared/documents/reconciliation-action-plan/csl-reflect-reconciliation-action-plan-rap-2023.pdf